Bernard-Soulier syndrome: Difference between revisions
Line 66: | Line 66: | ||
==Pathophysiology== | ==Pathophysiology== | ||
* It is thought that bernard soulier syndrome is the result of the absence or decreased [[expression]] of the [[Glycoprotein Ib|GPIb]]/IX/V complex on the surface of the [[Platelet|platelets]].<ref name="Lanza2006">{{cite journal|last1=Lanza|first1=François|journal=Orphanet Journal of Rare Diseases|volume=1|issue=1|year=2006|pages=46|issn=17501172|doi=10.1186/1750-1172-1-46}}</ref><ref name="BerndtAndrews2011">{{cite journal|last1=Berndt|first1=M. C.|last2=Andrews|first2=R. K.|title=Bernard-Soulier syndrome|journal=Haematologica|volume=96|issue=3|year=2011|pages=355–359|issn=0390-6078|doi=10.3324/haematol.2010.039883}}</ref> | * It is thought that bernard soulier syndrome is the result of the absence or decreased [[expression]] of the [[Glycoprotein Ib|GPIb]]/IX/V complex on the surface of the [[Platelet|platelets]].<ref name="Lanza2006">{{cite journal|last1=Lanza|first1=François|journal=Orphanet Journal of Rare Diseases|volume=1|issue=1|year=2006|pages=46|issn=17501172|doi=10.1186/1750-1172-1-46}}</ref><ref name="BerndtAndrews2011">{{cite journal|last1=Berndt|first1=M. C.|last2=Andrews|first2=R. K.|title=Bernard-Soulier syndrome|journal=Haematologica|volume=96|issue=3|year=2011|pages=355–359|issn=0390-6078|doi=10.3324/haematol.2010.039883}}</ref><ref name="FeghhiMunday2016">{{cite journal|last1=Feghhi|first1=Shirin|last2=Munday|first2=Adam D.|last3=Tooley|first3=Wes W.|last4=Rajsekar|first4=Shreya|last5=Fura|first5=Adriane M.|last6=Kulman|first6=John D.|last7=López|first7=Jose A.|last8=Sniadecki|first8=Nathan J.|title=Glycoprotein Ib-IX-V Complex Transmits Cytoskeletal Forces That Enhance Platelet Adhesion|journal=Biophysical Journal|volume=111|issue=3|year=2016|pages=601–608|issn=00063495|doi=10.1016/j.bpj.2016.06.023}}</ref> | ||
* The [[Glycoprotein Ib|GPIb]]/IX/V complex is the [[receptor]] for [[von Willebrand factor]] ([[Von Willebrand factor|vWF]]). | * The [[Glycoprotein Ib|GPIb]]/IX/V complex is the [[receptor]] for [[von Willebrand factor]] ([[Von Willebrand factor|vWF]]). | ||
* The [[Glycoprotein Ib|GPIb]]/IX/V complex plays a very important role in [[hemostasis]] and [[thrombosis]].<ref name="YanMo2011">{{cite journal|last1=Yan|first1=Rong|last2=Mo|first2=Xi|last3=Paredes|first3=Angel M.|last4=Dai|first4=Kesheng|last5=Lanza|first5=Francois|last6=Cruz|first6=Miguel A.|last7=Li|first7=Renhao|title=Reconstitution of the Platelet Glycoprotein Ib-IX Complex in Phospholipid Bilayer Nanodiscs|journal=Biochemistry|volume=50|issue=49|year=2011|pages=10598–10606|issn=0006-2960|doi=10.1021/bi201351d}}</ref><ref name="pmid11696542">{{cite journal |vauthors=Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN |title=Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin |journal=J. Biol. Chem. |volume=277 |issue=3 |pages=1662–8 |date=January 2002 |pmid=11696542 |doi=10.1074/jbc.M108319200 |url=}}</ref> | * The [[Glycoprotein Ib|GPIb]]/IX/V complex plays a very important role in [[hemostasis]] and [[thrombosis]].<ref name="YanMo2011">{{cite journal|last1=Yan|first1=Rong|last2=Mo|first2=Xi|last3=Paredes|first3=Angel M.|last4=Dai|first4=Kesheng|last5=Lanza|first5=Francois|last6=Cruz|first6=Miguel A.|last7=Li|first7=Renhao|title=Reconstitution of the Platelet Glycoprotein Ib-IX Complex in Phospholipid Bilayer Nanodiscs|journal=Biochemistry|volume=50|issue=49|year=2011|pages=10598–10606|issn=0006-2960|doi=10.1021/bi201351d}}</ref><ref name="pmid11696542">{{cite journal |vauthors=Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN |title=Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin |journal=J. Biol. Chem. |volume=277 |issue=3 |pages=1662–8 |date=January 2002 |pmid=11696542 |doi=10.1074/jbc.M108319200 |url=}}</ref> |
Revision as of 17:12, 1 August 2018
Bernard-Soulier syndrome | |
Bernard-Soulier syndrome. (Image courtesy of Melih Aktan M.D.) | |
ICD-10 | D69.1 |
ICD-9 | 287.1 |
OMIM | 231200 |
DiseasesDB | 1356 |
eMedicine | ped/230 |
MeSH | D001606 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Synonyms and keywords:
Overview
Historical Perspective
[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
There have been several outbreaks of [disease name], including -----.
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
Classification
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Pathophysiology
- It is thought that bernard soulier syndrome is the result of the absence or decreased expression of the GPIb/IX/V complex on the surface of the platelets.[1][2][3]
- The GPIb/IX/V complex is the receptor for von Willebrand factor (vWF).
- The GPIb/IX/V complex plays a very important role in hemostasis and thrombosis.[4][5]
- The GPIb/IX/V complex binds to von Willebrand factor (vWF) and that makes the initial contact adhesion of platelets to exposed vascular endothelium.[6]
- The GPIb/IX/V complex along with von Willebrand factor (vWF) also attach to ruptured plaque in damaged blood vessels.[7]
Causes
Disease name] may be caused by [cause1], [cause2], or [cause3].
OR
Common causes of [disease] include [cause1], [cause2], and [cause3].
OR
The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].
OR
The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.
Differentiating ((Page name)) from Other Diseases
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Epidemiology and Demographics
The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
OR
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
OR
In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
Patients of all age groups may develop [disease name].
OR
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
OR
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
OR
[Chronic disease name] is usually first diagnosed among [age group].
OR
[Acute disease name] commonly affects [age group].
There is no racial predilection to [disease name].
OR
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
[Disease name] affects men and women equally.
OR
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
The majority of [disease name] cases are reported in [geographical region].
OR
[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Risk Factors
There are no established risk factors for [disease name].
OR
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
OR
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
OR
Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Natural History, Complications, and Prognosis
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Diagnosis
Diagnostic Study of Choice
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
There are no established criteria for the diagnosis of [disease name].
History and Symptoms
The majority of patients with [disease name] are asymptomatic.
OR
The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].
Physical Examination
Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].
OR
Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
The presence of [finding(s)] on physical examination is diagnostic of [disease name].
OR
The presence of [finding(s)] on physical examination is highly suggestive of [disease name].
Laboratory Findings
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal among patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Electrocardiogram
There are no ECG findings associated with [disease name].
OR
An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
X-ray
There are no x-ray findings associated with [disease name].
OR
An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with [disease name].
OR
Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
CT scan
There are no CT scan findings associated with [disease name].
OR
[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
MRI
There are no MRI findings associated with [disease name].
OR
[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Other Imaging Findings
There are no other imaging findings associated with [disease name].
OR
[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
There are no other diagnostic studies associated with [disease name].
OR
[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Surgery
Surgical intervention is not recommended for the management of [disease name].
OR
Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
Surgery is the mainstay of treatment for [disease or malignancy].
Primary Prevention
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
References
- ↑ Lanza, François (2006). Orphanet Journal of Rare Diseases. 1 (1): 46. doi:10.1186/1750-1172-1-46. ISSN 1750-1172. Missing or empty
|title=
(help) - ↑ Berndt, M. C.; Andrews, R. K. (2011). "Bernard-Soulier syndrome". Haematologica. 96 (3): 355–359. doi:10.3324/haematol.2010.039883. ISSN 0390-6078.
- ↑ Feghhi, Shirin; Munday, Adam D.; Tooley, Wes W.; Rajsekar, Shreya; Fura, Adriane M.; Kulman, John D.; López, Jose A.; Sniadecki, Nathan J. (2016). "Glycoprotein Ib-IX-V Complex Transmits Cytoskeletal Forces That Enhance Platelet Adhesion". Biophysical Journal. 111 (3): 601–608. doi:10.1016/j.bpj.2016.06.023. ISSN 0006-3495.
- ↑ Yan, Rong; Mo, Xi; Paredes, Angel M.; Dai, Kesheng; Lanza, Francois; Cruz, Miguel A.; Li, Renhao (2011). "Reconstitution of the Platelet Glycoprotein Ib-IX Complex in Phospholipid Bilayer Nanodiscs". Biochemistry. 50 (49): 10598–10606. doi:10.1021/bi201351d. ISSN 0006-2960.
- ↑ Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN (January 2002). "Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin". J. Biol. Chem. 277 (3): 1662–8. doi:10.1074/jbc.M108319200. PMID 11696542.
- ↑ Feghhi S, Munday AD, Tooley WW, Rajsekar S, Fura AM, Kulman JD, López JA, Sniadecki NJ (August 2016). "Glycoprotein Ib-IX-V Complex Transmits Cytoskeletal Forces That Enhance Platelet Adhesion". Biophys. J. 111 (3): 601–608. doi:10.1016/j.bpj.2016.06.023. PMC 4982925. PMID 27508443.
- ↑ Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, López JA (September 1999). "The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin". J. Exp. Med. 190 (6): 803–14. PMC 2195629. PMID 10499919.